TABLE 2.
Distribution of cardiovascular and stroke event, and corresponding event rate among all ASPirin in Reducing Events in the Elderly study participants by baseline hypertensive status
| Pre-2017 hypertensive (N = 14 213) | Reclassified hypertensive (N = 2354) | Normotensive (N = 2547) | |
|---|---|---|---|
| Cardiovascular disease event (922, 10.97 events per 1000 person-years) | |||
| Number of event (n, %) | 753 (5.3%) | 93 (4.0%)a | 76 (3.0%)a |
| Event rate per 1000 person-year (95% CI) | 12.1 (11.2–13.0) | 8.9 (7.3–11.0)a | 6.8 (5.4–8.5)a |
| Hazard ratio (95% CI) | |||
| Unadjusted | 1.79 (1.42–2.27) P < 0.001 | 1.33 (0.98–1.80) P = 0.07 | 1.00 |
| Adjustedb | 1.60 (1.26–2.02) P < 0.001 | 1.26 (0.93–1.71) P = 0.14 | 1.00 |
| Stroke-only eventc (315, 3.7 events per 1000 person-years) | |||
| Number of event (n, %) | 252 (1.8%) | 36 (1.5%) | 27 (1.1%)a |
| Event rate per 1000 person-years (95% CI) | 4.0 (3.5–4.5) | 3.4 (2.5–4.8) | 2.4 (1.6–3.5)a |
| Hazard ratio (95% CI) | |||
| Unadjusted | 1.67 (1.13–2.49) P = 0.01 | 1.44 (0.87–2.37) P = 0.15 | 1.00 |
| Adjustedb | 1.52 (1.02–2.27) P = 0.04 | 1.39 (0.84–2.29) P = 0.20 | 1.00 |
a
Significant difference (P < 0.05) observed with ‘Pre-2017 hypertensive’ group.
b
Significant difference (P < 0.05) observed between ‘reclassified hypertensive’ and ‘normotensive’ groups.
c
Adjusted for age, sex, ethnicity, current smoking, country of residence, treatment (aspirin/placebo).
c
Stroke included cases that were adjudicated as ischemic stroke, cases for which stroke type was uncertain after adjudication, and cases of ischemic stroke with haemorrhagic transformation.